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Methylchloroisothiazolinone (MCI)/methylisothiazolin-
one (MI), a widely used preservative/biocide, was
included in the European baseline series in 1988 at a
concentration of 100 ppm (0.01%) in a ratio of 3:1 (1).
Although recently it has been recommended to be tested
at 200 ppm (0.02%), many centres still test it at 100 ppm
(2). MCI/MI is also included in the TRUE Test®, offering
an alternative patch test technique. The objective of the
current investigation was to compare the diagnostic
performance of MCI/MI 0.01% aq. with MCI/MI in the
TRUE Test®.
Methods
Between April 2013 and August 2016, a total of 1122
consecutive patients were patch tested with our depart-
mental baseline series, of whom 1115 (99.4%) were
tested simultaneously with bothMCI/MI 4𝜇g/cm2 (TRUE
Test®; Mekos, Hillerød, Denmark) and MCI/MI 0.01%
aq. (Trolab; Almirall Hermal, Reinbek, Germany), cor-
responding to a dose per unit area of 3𝜇g/cm2, in Van
der Bend® square chambers (van der Bend, Brielle, The
Netherlands), attached to the backwith Fixomull stretch®
(BSN Medical, Hamburg, Germany). Twentymicrolitres
of the aqueous solution of MCI/MI was applied to the
chambers with a micropipette. The patch tests were
applied on the back for 48h under occlusion, and read-
ings were performed on day (D) 3 and D7 according to
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ESCD guidelines (3). The maximum patch test reactions
were aggregated as the patch test outcome. In case of a
positive reaction (+, ++, or +++), clinical relevance was
determined on basis of patient history, clinical examina-
tion, and exposure patterns,with possible outcomes being
unlikely/not, possible, probable, and certain. Statistical
analyses were performed with SPSS (version 23.0; SPSS,
Chicago, IL, USA), and guidelines for contact allergy
data were followed (4). The McNemar test was used to
compare the strength of reactions of both patch test
preparations.
Results
The MOAHLFA index for the investigated patient group
was as follows: male, 32.6%; occupational dermati-
tis, 24.1%; atopic dermatitis, 40.9%; hand, 34.0%;
leg, 22.4%; face, 3.7%; and age ≥40 years, 57.5%.
A total of 14.4% (n=161) of patients had a positive
reaction to one of the MCI/MI preparations; 13.6%
(95%CI: 11.6–15.6%) had positive reactions to MCI/MI
TRUE Test®, and 7.2% (95%CI: 5.7–8.7%) had positive
reactions to MCI/MI 3𝜇g/cm2 aq. The patch test reac-
tions to MCI/MI TRUE Test® were significantly stronger
(p<0.001). Table 1 shows the patterns of reactions to
both patch test preparations in greater detail. Of all
patients with positive reactions to MCI/MI TRUE Test®
(n=152), 81 (53.3%) did not have positive reactions
to MCI/MI 3𝜇g/cm2 aq. Furthermore, 35 of these 81
reactions were strong to extreme positive reactions. Con-
versely, of the 80 patients who had positive reactions to
MCI/MI 3𝜇g/cm2 aq., 9 (11.3%) did not react to MCI/MI
TRUE Test®.
The clinical relevance of all positive reactions was
determined, and is shown in Table 2. Of all positive reac-
tions to MCI/MI TRUE Test®, 88.8% (135/152) had some
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Table 1. Relationship between patch test reactions ofmethylchloroisothiazolinone (MCI)/methylisothiazolinone (MI) TRUETest® andMCI/MI
0.01% aq.
MCI/MI 0.01% aq.
Negative Irritant Doubtful + ++ +++ Total
MCI/MI TRUE Test® Negative 931 2 14 8 1 0 956
Irritant 1 0 0 0 0 0 1
Doubtful 5 0 1 0 0 0 6
+ 37 0 9 15 1 0 62
++ 27 0 2 29 16 0 74
+++ 6 0 0 4 5 1 16
Total 1007 2 26 56 23 1 1115
Table 2. The clinical relevance of all positive reactions to either
methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI)
TRUE Test® or MCI/MI 0.01% aq.
Clinical
relevance










Unlikely/not 7.2 (11) 11.3 (9)
Unknown 4.0 (6) 1.3 (1)
Possible 38.8 (59) 32.5 (26)
Probable 27.0 (41) 23.8 (19)
Certain 23.0 (35) 31.3 (25)
degree of clinical relevance (ranging from possible to
certain), as compared with 87.5% (70/80) of positive
reactions to MCI/MI 3𝜇g/cm2 aq. For the 9 patients with
positive reactions to MCI/MI 3𝜇g/cm2 aq. but without
positive reactions to MCI/MI TRUE Test®, six reactions
were considered to be of possible clinical relevance, two
of probable clinical relevance, and one of no clinical
relevance. Conversely, for the 81 patients with positive
reactions to MCI/MI TRUE Test® but without positive
reactions to MCI/MI 3𝜇g/cm2 aq., 90.1% (n=73) of
reactions had some degree of clinical relevance (39 possi-
ble, 24 probable, and 10 certain), three reactions were of
unknown clinical relevance, and the remaining five were
of no clinical relevance. This means that, if this cohort
had been patch tested solely with MCI/MI 3𝜇g/cm2 aq.,
there would have been 73 missed reactions, constituting
6.5% of all consecutively patch tested patients.
Discussion
Although the prevalence of MCI/MI contact allergy in
patch test populations remained relatively stable at 2.5%
for a long period of time, recent publications have shown
it to be rapidly rising (5–8). The most recent publication
of the European Surveillance System on Contact Allergies
(ESSCA) showed a standardized prevalence of 7.3% for
contact allergy to MCI/MI 0.01% in 2013–2014, which
is similar to our results (9).
More surprising in the current results is the high pro-
portion of positive reactions to the TRUE Test® prepara-
tion, which was almost twice as high, at 13.6%. A large
majority of these positive reactions were deemed to have
at least some degree of clinical relevance, making the
possibility of false positives less likely. The concentration
of MCI/MI in the TRUE Test®, at 4𝜇g/cm2, is slightly
higher than the 3𝜇g/cm2 of MCI/MI 0.01% aq., which
explains part of this discrepancy, as MCI/MI has a steep
dose–response curve (7). This also illustrates that, besides
dose, other factors, such as vehicle, also affect elicitation
responses, as MCI/MI is tested in povidone in the TRUE
Test® (10). A major limitation of the current study is
that MCI/MI was not tested at a concentration of 0.02%
(200 ppm or 6𝜇g/cm2), which would have allowed an
even better comparison of the different patch test tech-
niques, but this might be addressed by future studies.
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